ganciclovir indications/contra

Stem definitionDrug idCAS RN
antivirals bicyclic heterocycle compounds 1277 82410-32-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ganciclovir
  • denosine
  • gancyclovir
  • hydroxyacyclovir
  • natclovir
  • ganciclovir sodium
An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
  • Molecular weight: 255.23
  • Formula: C9H13N5O4
  • CLOGP: -2.54
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 4
  • TPSA: 134.99
  • ALOGS: -1.35
  • ROTB: 5

Drug dosage:

DoseUnitRoute
3 g O
0.50 g P

Approvals:

DateAgencyCompanyOrphan
June 23, 1989 FDA ROCHE PALO

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytomegalovirus infection 922.93 84.11 161 889 4346 3380463
Drug resistance 426.84 84.11 85 965 4578 3380231
Pancytopenia 285.68 84.11 80 970 18740 3366069
Bone marrow failure 264.44 84.11 64 986 8423 3376386
Neutropenia 200.88 84.11 70 980 33316 3351493
Cytomegalovirus chorioretinitis 196.56 84.11 31 1019 411 3384398
Cytomegalovirus viraemia 193.51 84.11 33 1017 726 3384083
Leukopenia 167.45 84.11 51 999 15772 3369037
Cytomegalovirus colitis 161.31 84.11 26 1024 398 3384411
Renal impairment 151.99 84.11 49 1001 18212 3366597
Drug ineffective 149.87 84.11 82 968 116008 3268801
Aspergillus infection 147.37 84.11 30 1020 1757 3383052
Cytomegalovirus test positive 137.85 84.11 25 1025 788 3384021
Multiple organ dysfunction syndrome 133.56 84.11 42 1008 14368 3370441
Pneumonia cytomegaloviral 126.62 84.11 22 1028 539 3384270
Renal failure 116.74 84.11 47 1003 32893 3351916
Thrombocytopenia 113.63 84.11 47 1003 35221 3349588
Pyrexia 106.06 84.11 58 992 81057 3303752
Transplant rejection 103.00 84.11 23 1027 2088 3382721
Pneumonia 102.40 84.11 54 996 70089 3314720
Sepsis 93.66 84.11 40 1010 32333 3352476
Graft versus host disease 93.43 84.11 22 1028 2525 3382284

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC J05AB06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
ATC S01AD09 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Antivirals
CHEBI has role CHEBI:36044 antiviral drug
CHEBI has role CHEBI:35441 antiinfective agent
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
FDA EPC N0000175461 Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
FDA MoA N0000020060 DNA Polymerase Inhibitors
FDA Chemical/Ingredient N0000175459 Nucleoside Analog
FDA EPC N0000175466 Nucleoside Analog Antiviral

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Cytomegaloviral retinitis indication 22455005
Herpes simplex dendritic keratitis indication 29943008
Paroxysmal supraventricular tachycardia indication 67198005
CMV Retinitis in Immunocompromised Patients indication
Prevention of CMV Disease After Kidney-Pancreas Transplantation indication
Prevention of CMV Disease After Organ Transplant indication
Myocardial Perfusion Imaging Adjunct indication
CMV Retinitis in AIDS Patients indication
Prevention of CMV Disease After Cardiac Transplantation indication
Prevention of CMV Disease in Advanced HIV Patients indication
Prevention of CMV Disease After Kidney Transplantation indication
Endophthalmitis contraindication 1847009 DOID:4692
Pericarditis contraindication 3238004 DOID:1787
Reduced visual acuity contraindication 13164000
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Disorder of autonomic nervous system contraindication 15241006
Complete atrioventricular block contraindication 27885002
Hypovolemia contraindication 28560003
Acute cerebrovascular insufficiency contraindication 29322000
Vitreous hemorrhage contraindication 31341008
Transplantation of heart contraindication 32413006
Dehydration contraindication 34095006
Sick sinus syndrome contraindication 36083008 DOID:13884
Retinal detachment contraindication 42059000 DOID:5327
Low blood pressure contraindication 45007003
Acute nephropathy contraindication 58574008
Aortic valve stenosis contraindication 60573004 DOID:1712
Left to right cardiovascular shunt contraindication 66130006
Mitral valve stenosis contraindication 79619009 DOID:1754
Pulmonary emphysema contraindication 87433001
Kidney disease contraindication 90708001 DOID:2527
Bilateral cataracts contraindication 95722004
Respiratory alkalosis contraindication 111378004
Eye infection contraindication 128351009
Uveitis contraindication 128473001 DOID:13141
Second degree atrioventricular block contraindication 195042002
Asthma contraindication 195967001 DOID:2841
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Aplastic anemia contraindication 306058006 DOID:12449
Left main coronary artery disease contraindication 371804009
Acute coronary syndrome contraindication 394659003
Respiratory insufficiency contraindication 409623005
Breastfeeding (mother) contraindication 413712001
Granulocytopenic disorder contraindication 417672002 DOID:12987
Severe Bone Marrow Depression contraindication
Syncope due to Bradycardia contraindication
Supraventricular tachycardia off-label use 6456007
Cytomegalovirus infection off-label use 28944009
CMV-Related Polyradiculopathy in AIDS Patients off-label use
Prevention of Cytomegalovirus Disease off-label use

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.97 acidic
pKa2 12.38 acidic
pKa3 12.98 acidic
pKa4 3.68 Basic
pKa5 2.12 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Metabotropic glutamate receptor 5 GPCR Ki 5.41 WOMBAT-PK
Metabotropic glutamate receptor 1 GPCR Ki 6.05 WOMBAT-PK
DNA polymerase catalytic subunit Enzyme INHIBITOR WOMBAT-PK CHEMBL
Thymidine kinase Kinase WOMBAT-PK
Purine nucleoside phosphorylase Unclassified Kd 4.80 CHEMBL
Capsid scaffolding protein Enzyme EC50 6.07 WOMBAT-PK

External reference:

scroll-->
IDSource
4019764 VUID
N0000147855 NUI
C0017066 UMLSCUI
D00333 KEGG_DRUG
02L083W284 UNII
107910-75-8 SECONDARY_CAS_RN
DB01004 DRUGBANK_ID
3454 PUBCHEM_CID
4678 RXNORM
372848001 SNOMEDCT_US
78025001 SNOMEDCT_US
4775 MMSL
d00066 MMSL
76587005 SNOMEDCT_US
4019764 VANDF
N0000006495 NDFRT
N0000147855 NDFRT
177021 MMSL
003444 NDDF
CHEMBL182 ChEMBL_ID
CHEBI:465284 CHEBI
CHEMBL1200850 ChEMBL_ID
6023 INN_ID
D015774 MESH_DESCRIPTOR_UI
GA2 PDB_CHEM_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Cytovene HUMAN PRESCRIPTION DRUG LABEL 1 0004-6940 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA 19 sections
ZIRGAN HUMAN PRESCRIPTION DRUG LABEL 1 24208-535 GEL 1.50 mg OPHTHALMIC NDA 14 sections
ganciclovir HUMAN PRESCRIPTION DRUG LABEL 1 25021-185 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 18 sections
Ganciclovir HUMAN PRESCRIPTION DRUG LABEL 1 42023-173 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 12 sections
ganciclovir HUMAN PRESCRIPTION DRUG LABEL 1 47351-077 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS Approved Drug Product Manufactured Under Contract 1 sections
GANCICLOVIR HUMAN PRESCRIPTION DRUG LABEL 1 51754-2500 INJECTION, SOLUTION 2 mg INTRAVENOUS NDA 18 sections
GANCICLOVIR HUMAN PRESCRIPTION DRUG LABEL 1 63304-636 CAPSULE 250 mg ORAL ANDA 15 sections
GANCICLOVIR HUMAN PRESCRIPTION DRUG LABEL 1 63304-637 CAPSULE 500 mg ORAL ANDA 15 sections
Ganciclovir HUMAN PRESCRIPTION DRUG LABEL 1 63323-315 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 13 sections
ganciclovir HUMAN PRESCRIPTION DRUG LABEL 1 69292-015 GEL 1.50 mg OPHTHALMIC NDA authorized generic 14 sections